For five years, John Eldridge and his team at Profectus Bioscience have developed and tested their Ebola vaccine. First it was on guinea pigs, then monkeys. 

At that point, Eldridge realized monkeys weren't getting sick.

I’m so used to hearing bullish projections on digital health, it’s refreshing when someone contradicts that assessment. Maybe contradict is the wrong word. But Thomas Rodgers, who joined McKesson Ventures last month after a couple of years with Cambia Health Solutions, thinks it will take a lot longer for the technology to enjoy mainstream adoption.

“I think it will be 15-20 years until it is intertwined with medical care. It will take a shift away from fee-for-service and it will also take generational change. Millennials who grew up with technology will need to start getting sick.”

In the decade after the founding of the BioCrossroads initiative, money spent on life sciences research and companies more than doubled, to more than $25 billion, according to a new report released Thursday by the Indianapolis-based life sciences business development group.

That infusion of money—much of which came from out of state—has helped Indiana companies and universities increase the number of life sciences patents, technology licenses, startups and venture capital deals faster than the rest of the nation, according to the report.

The Hong Kong scientist who invented a simple blood test to show pregnant women if their babies have Down syndrome is now testing a similar technology for cancer.

Yuk Ming “Dennis” Lo says screening for signs of cancer from a simple blood draw could cost as little as $1,000. The test works by studying DNA released into a person’s bloodstream by dying tumor cells.

Novavax Inc.'s singular drug development approach to a possible Ebola vaccine may not only help stop the spread of a future pandemic but also reap major bottom-line rewards.

That's what CFO Barclay "Buck" Phillips told me this week after the Gaithersburg-based company announced it planned to begin Phase 1 clinical trials by December. Novavax announced this week at the 8th Vaccine and ISV Conference in Philadelphia that it's the only company targeting the newest strain of the virus which emerged in Guinea this year and has killed thousands in West Africa.

New York Medical College will inaugurate its biotechnology incubator Wednesday.

The multimillion-dollar BioInc@NYMC at 7 Dana Drive in Valhalla will offer space to scientists, entrepreneurs and biotech firms.

Johns Hopkins University is the 11th best university in the world, according to the first ever Best Global University rankings published by U.S. News & World Report on Tuesday. The rankings use different criteria than those used for the annual "best colleges" list, on which Johns Hopkins ranked 12th last month.

The new rankings include 500 universities in 49 countries. Sixteen of the top 20 universities are in the U.S., including Harvard, which tops the rankings.

As Penn prepares for the ceremonial groundbreaking of the Pennovation Center on Friday, Drexel University’s Innovation Neighborhood is still searching for a master developer.

Both universities are pushing to become incubators of commercial enterprise and educational advancement. Since purchasing a 23-acre site on Grays Ferry Avenue in 2010, Penn has been working to develop the Pennovation Center — a three-story, 52,000-square-foot complex that will serve as a hub for research and business ventures. In addition to the ceremonial groundbreaking on Friday, Penn President Amy Gutmann will host a series of “Pennovation Talks” at the South Bank campus.

International VC firm SOSVentures is capitalizing on the now buzz worthy biotech investment trend with the creation of IndieBio, the first accelerator to focus on just life sciences.

Y Combinator raised a few eyebrows when it accepted five biotech companies out of the 80 startups in its program this last summer. That was a first for the Silicon Valley accelerator. But IndieBio partners tell us they were already thinking along those lines when Y Combinator started making in-roads with those life sciences startups.

The average board of directors in the biotech world is roughly 90% male, according to a new analysis, and more than half of all industry boardrooms host no women whatsoever, striking numbers that illustrate a sector that struggles with diversity.

Liftstream, a recruitment services outfit, analyzed nearly 1,150 life sciences companies in the U.S. and EU, finding that biotech's boardrooms tend toward Y chromosomes. Among drug developers with fewer than 1,000 workers, women held just 10% of available board seats, and fewer than 4% had female chairs. C-suites didn't fare much better, as women accounted for fewer than 25% of leadership teams across the industry.

Strand Life Sciences (Strand) representatives will demonstrate new capabilities of the company's variant interpretation and reporting software, StrandOmics at the Association For Molecular Pathologist (AMP) 2014 Annual Meeting to be held from November 12th to 15th in National Harbor, Maryland. The 20th anniversary meeting's theme is "Realizing the Dream of Precision Medicine," with a special address by Dr. Francis Collins, Director of the National Institute of Health. At AMP, Strand will host a workshop on the innovative developments and application of its StrandOmics software, plus new expansion efforts in Personalized Medicine.

Advent Life Sciences today announced the closing of Advent Life Sciences Fund II (ALSF II), a £145.5M (USD 235M) venture capital fund raised to seed and build life sciences companies in the UK, Europe and the US. The Fund will back entrepreneurs and early-stage and mid-stage companies with the potential to deliver first- or best-in-class breakthrough products for unmet medical needs. The Fund, which quickly exceeded its target, was raised entirely from independent financial investors including funds-of-funds, pension funds, and family offices.

"We thank our returning and new LPs for the strength of their support, which allowed us to raise the commitments for this Fund in a matter of weeks" said Raj Parekh, General Partner. He added "The interest from LPs and demand for the Fund, particularly in current markets, is in large part a recognition of the scientific and medical entrepreneurs, CEOs and Management teams whose commitment, vision and energy is enabling our portfolio companies to bring important medical innovations to patients. It is a privilege to work with them."

Funding and Research Opportunities

The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:

NIH Guide Notices:

• Notice to Extend PAR-12-033 "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Etiology, Diagnosis, Pathophysiology, and Treatment (R21)" by an Additional Funding Cycle
  (NOT-OD-15-007) Office of Research on Women's Health
• Notice of Clarification of 4-Year Limit of Postdoctoral Research Eligibility for K99 Applicants for PA-14-042 NIH Pathway to Independence Award (Parent K99/R00)
  (NOT-OD-15-013) Office of the Director, NIH
• Notice of Revised NIH Definition of Clinical Trial
  (NOT-OD-15-015) National Institutes of Health

Requests for Applications (RFAs):

• Pediatric HIV/AIDS Cohort Study (PHACS) Coordinating Center (CC) (U01)
  (RFA-HD-15-027)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): January 02, 2015
• Pediatric HIV/AIDS Cohort Study (PHACS) Data and Operations Center (DOC) (U01)
  (RFA-HD-15-029)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Allergy and Infectious Diseases
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of Mental Health
  National Institute of Neurological Disorders and Stroke
  Office of AIDS Research
  Application Receipt Date(s): January 02, 2015
• NIH Director's Early Independence Awards (DP5)
  (RFA-RM-14-004)
  NIH Roadmap Initiatives
  National Institute of Dental and Craniofacial Research
  Application Receipt Date(s): January 30, 2015

Please note that most links to RFAs, PAs, and Guide Notices will take you to the NIH Web site. RFPs will take you to FedBizOpps. Links to RFPs will not work past their proposal receipt date. Archived versions of RFPs posted on FedBizOpps can be found on the FedBizOpps site using the FedBizOpps search function. Under “Document to Search,” select Archived Documents.

Another early-stage biotech investor has clocked in with a new fund. London-based Advent Life Sciences said Tuesday it has closed a $235 million vehicle, its second specialized fund since the tech and life science investors of Advent Venture Partners went separate ways last decade.

The firm used to invest in tech and life sciences from a single fund, Advent Life Sciences general partner Raj Parekh said. But in the middle of last decade, as the old Advent began what Parekh (pictured) called a “generational handover,” the tech side looked toward mid-market, growth equity investments, while the life sciences partners wanted to be involved in company formation.

Paragon Bioservices, Inc. ("Paragon"), a privately held contract research and manufacturing organization whose mission is to accelerate the development and manufacturing of biopharmaceuticals and vaccines, announced today that it has raised $13 Million in a Series A Preferred Stock financing led by NewSpring Capital and Camden Partners.

NewSpring Capital, headquartered in Radnor, PA, invests in dynamic companies, partnering with management teams to accelerate growth and develop their businesses into market leaders. Camden Partners, located in Baltimore, MD, operates private equity funds that provide growth capital to emerging companies in the Technology-Enabled Business Services, Healthcare, and Educational sectors. 1st BridgeHouse Securities and Evergreen Advisors, LLC, Columbia, MD acted as advisors to Paragon Bioservices.  All securities transactions were conducted through 1st BridgeHouse Securities, LLC, a member of FINRA and SIPC.

Maryland Department of Health and Mental Hygiene officials announced early Tuesday that the patient tested negative for Ebola. The department said that person will continue to receive the appropriate treatment.

A patient who was being isolated at the University of Maryland Medical Center in Baltimore for Ebola testing Monday evening does not have the deadly virus, officials announced Tuesday.

New Enterprise Associates is preparing to raise the largest venture capital fund in history, Fortune has learned.

The 37 year-old firm has told investors to expect formal documents by year-end for its fifteenth fund, which is expected to target approximately $2.8 billion. That’s nearly a 10% increase from the $2.6 billion NEA raised for Fund 14 in the summer of 2012, which itself was the industry’s record-holder (just edging out a $2.56 billion fund raised in 2006 by Oak Investment Partners). It also told prospective investors that longtime partner Scott Sandell will be promoted to co-managing partner, alongside Peter Barris.

Two new studies in the New England Journal of Medicine rocked the world of celiac research, both proving that scientists have a ways to go in their understanding of celiac disease, which affects about 1% of the population, whether they know it or not.

One Italian study wondered if the age at which gluten is introduced into the diet could affect a person’s likelihood of developing the autoimmune disease—so they kept gluten away from newborns for a year. To the shock of the researchers, delaying exposure to gluten didn’t make a difference in the long run. In some cases it delayed the onset of the disease, but it didn’t stop people from developing the disease, for which there is no cure.

Montgomery County has chosen two partners to begin planning a “kitchen incubator” to provide business training and commercial kitchen space to budding local culinary entrepreneurs.

The county is partnering with Union Kitchen, which runs a for-profit commercial kitchen space in the District, and Streetsense, the Bethesda-based design and development firm, to plan how the incubator will be set up.

Cancer’s become a core area of venture capital interest, particularly given the rise of personalized medicine. But in a cluttered marketplace it’s tough to differentiate the worthy from the chaff. Here are some observations from a panel of investors said at the Cleveland Clinic Medical Innovation Summit Monday:

When it comes to deadly infections, Ebola is certainly the virus du jour. But in the U.S., the risk of contracting the Ebola virus is minuscule compared to the risk of becoming infected with one of several antibiotic-resistant bacteria, sometimes known as “superbugs.”

Saturday, November 8, 2014 9 a.m. - 2 p.m.

University of Maryland, College ParkVan Munching Hall/ Smith School of Business

Advancing Tomorrow’s Leaders + STEM (ATLAS) is a one-day college and career symposium hosted by the MdBio Foundation and Tech Council of Maryland, in partnership with Prince George’s County Public Schools (PGCPS), the University of Maryland’s Office of Corporate and Foundation Relations and Elizabeth Seton High School. This inaugural Prince George’s County-based symposium is the third ATLAS event in Maryland, and is part of a larger initiative and formal partnership with PGCPS to encourage interest of high school juniors, seniors and college undergrads, who are typically underrepresented in Science Technology Engineering and Math (STEM) fields.

Baltimore health IT startup Emocha Mobile Health Inc. is partnering with Baltimore City to test out its medication adherence application with tuberculosis patients.

Emocha's miDOT records video of patients taking their medication, notes symptoms and sends a report to doctors. The company is letting Balitmore's health department use the program for free in an effort to begin building market interest and credibility for the program.

Antti Korhonen - NIST-TEDCO* Entrepreneur-in-Residence

Thursday, November 6, 2014 10:30 AM - 12:00 Noon Admin Bldg (Bldg 101), Lecture Room A

Recognize an invention’s value by developing its “Value Proposition”

Learn about discovering the “Value Proposition.” Something every NIST researcher and manager needs to know

• Inventions can be 
• smart and clever—and stay in the lab forever
• scientific breakthroughs—but still have no commercial value
• Inventions that are patented are well protected in the market—assuming they have market value that needs protection
• Inventions with the greatest social and economic impact are those having clearly defined market value

Swiss pharmaceutical group Roche hopes to obtain fast-track US approval for a rapid diagnostic test for Ebola, its director general said in an interview published Sunday, amid the worst-ever outbreak of the killer disease.

The diagnostic test is ready for use in scientific research but the company now wants to register it for clinical use.

As a partner at Norwest Venture Partners (NVP), Casper de Clercq has seen countless digital health startups try to get solutions off the ground. He’s also seen many fail.

According to de Clercq, 60 to 70 percent of digital health startups are likely to fail because they are unclear about their go-to market strategy, and don’t have a good understanding of who’s ultimately going to pay for their product.

The University of California recently announced its entry into the venture capital arena with a $250 million commitment to spinning promising technologies out of its top-notch, 10-campus system. Perhaps every major research university in the US — collectively, recipients of over $40 billion in federal research funding yearly, not to mention the inflows of corporate research funds — wishes to emulate Stanford’s success in capitalizing on the market successes of university-developed technology (think Google).

Pharma giant GlaxoSmithKline (GSK) might plan an initial public offering (IPO) of a minority stake in ViiV Healthcare, a global business focused on developing treatments for HIV, reports FierceBiotech.

Created five years ago, ViiV is GSK’s majority-owned joint venture with Pfizer and Shionogi. In the past 18 months, the Food and Drug Administration (FDA) approved two new HIV treatments from ViiV: Tivicay (dolutegravir) and the combo-tablet Triumeq, which includes Tivicay. These successes come at a time when GSK is planning to slash nearly $1.6 billion from its annual budget.

It’s no secret that Washington has a funding problem, with lawmakers and federal departments currently operating under unprecedented fiscal constraints.

It’s a very different story for the city’s entrepreneurs.

Pfizer Inc. has officially transferred an unused building on its campus here to Connecticut United for Research Excellence for use as a bioscience incubator hub, Gov. Dannel P. Malloy announced Friday.

The 24,000-square-foot Building 286 will become CURE Innovation Commons, which is expected to be fully operational by July 1, 2015.

Sucampo Pharmaceuticals Inc. on Thursday named Peter Kiener — whose past roles includes CEO of Zyngenia and head of biologics R&D for MedImmune — as its chief scientific officer.

Kiener, a heavyweight research hire, worked alongside Sucampo CEO Peter Greenleaf at MedImmune, where Greenleaf served as president until early 2013. Kiener then departed to launch Zyngenia Inc., a New Enterprise Associates-funded biotech focusing on antibody-based therapeutics, which he departed last year.

In early drug dis­covery, you need a starting point, says North­eastern Uni­ver­sity asso­ciate pro­fessor of chem­istry and chem­ical biology Michael Pollastri.

In a new research paper pub­lished Thursday in the journal PLOS-Neglected Trop­ical Dis­eases, Pol­lastri and his col­leagues present hun­dreds of such starting points for poten­tially treating Human African try­panoso­mi­asis, or sleeping sick­ness, a deadly dis­ease that affects thou­sands of people annually.

The technology for creating new tissues from stem cells has taken a giant leap forward. Two tablespoons of blood are all that is needed to grow a brand new blood vessel in just seven days. This is shown in a new study from Sahlgrenska Acadedmy and Sahlgrenska University Hospital published in EBioMedicine. Just three years ago, a patient at Sahlgrenska University Hospital received a blood vessel transplant grown from her own stem cells.

Suchitra Sumitran-Holgersson, Professor of Transplantation Biology at Sahlgrenska Academy, and Michael Olausson, Surgeon/Medical Director of the Transplant Center and Professor at Sahlgrenska Academy, came up with the idea, planned and carried out the procedure.

Qiagen has announced the introduction of expanded functionality for its range of bioinformatics workflow solutions.

New capabilities for the Ingenuity Variant Analysis and CLC Cancer Research Workbench solutions were unveiled at the American Society of Human Genetics annual meeting, which recently concluded in San Diego.

Regression models, Monte Carlo simulations, and other methods for predicting what’s around the corner have been in use for decades. It’s only recently, though, that advances in information technology have made it possible for predictive tools to access and manipulate big data, and to do so continuously — accelerating the generation of insights, and opening up opportunities to anticipate issues with unprecedented precision. Think of the colleges that are increasingly able to identify students at risk of dropping out and intervene before they do. Or lenders’ enhanced abilities to gauge credit risk. Energy, agriculture, insurance, retail, human resources — no industry is unaffected. But nowhere is the potential of this new era of opportunity more apparent and exciting than it is in health care.